Unlocking the Challenges of Uncontrolled Hypertension
Published: 28 June 2024
-
Views:
7587
-
Likes:
7
-
Views:
7587
-
Likes:
7
-
22m 27sPart 4 Audience Q&A
-
5m 17sPart 1 | Session 1 Case Presentation Thomas Weber, Bryan Williams, Erika SW Jones
-
8m 18sPart 1 | Session 2 Panel Discussion Thomas Weber, Bryan Williams, Erika SW Jones
-
2m 21sPart 2 | Session 1 Case Presentation Continued Thomas Weber, Bryan Williams, Erika SW Jones
-
5m 37sPart 2 | Session 2 Audience Polls & Panel Discussion Thomas Weber, Bryan Williams, Erika SW Jones
Overview
The long term clinical implications of uncontrolled hypertension are well documented, but almost half of those with hypertension remain inadequately treated. In this symposium, our panel of three leading hypertension experts, Prof Thomas Weber (Klinikum Wels-Grieskirchen, Wels, AT), Prof Bryan Williams (University College London, London, UK) and Prof Erika Jones (University of Cape Town, Cape Town, SA), examine the current state of medical therapy, the barriers to optimal treatment and the underlying mechanisms driving uncontrolled hypertension, including the pivotal role played by aldosterone.
Presented, and recorded, at ESH 2024, in Berlin, DE. ay also be interested in: Cracking the Code of Uncontrolled Hypertension – S
Learning Objectives
- Describe the long-term clinical impact of uncontrolled hypertension
- Apply guideline-directed management to a patient case study
- Evaluate the challenges and limitations of current management options for uncontrolled hypertension
- Describe the role of aldosterone in uncontrolled hypertension
Target Audience
- Hypertension (Htn) Specialists
- Cardiologists / Internists
- Nephrologists
- GPs with an Interest in Htn
More from this programme
Part 1
Clinical Impact of Uncontrolled Htn and Case Presentation
In this first part, Prof Williams presents a patient case of a 56 year old male with a 20+ year history of hypertension. He presents the primary investigations and following this the panel discuss what is driving the uncontrolled hypertension, the clinical risk and current guideline-directed options.
| 2 sessions | |
| Case Presentation | Watch now |
| Panel Discussion | Watch now |
Part 2
Current Treatment Barriers and Limitations
Following presentation of the secondary investigations, the panel further discuss the underlying cause. Prof Weber then runs two audience polls to understand the significant cause of uncontrolled hypertension and barriers for currently available drugs to treat uncontrolled hypertension in your clinical practice. Following this, the panel discuss issues with the current Htn standard of care.
Part 3
What Drives Uncontrolled Hypertension?
Prof Jones presents on other contributing factors for uncontrolled hypertension. She discusses adherence, the pathophysiology of hypertension, second line therapy and pheontyping patients.
Part 4
Audience Q&A
The session closes with an engaging audience Q&A.
| 1 session | |
| Audience Q&A | Watch now |
Faculty Biographies
Erika SW Jones
Nephrology and Hypertension Specialist
Erika Jones is Associate Professor in the Division of Nephrology and Hypertension at the University of Cape Town and Groote Schuur Hospital in Cape Town, SA.
Dr Jones interests are particularly in hypertension, having done her PhD in this area. One of the aspects of hypertension that she is studying currently and which is of major concern to nephrologists in Cape Town, is the rising incidence of young hypertensives with end stage renal disease in relation to methamphetamine usage.